Global Late Stage Chronic Kidney Disease Drugs Market Growth (Status and Outlook) 2025-2031
According to this study, the global Late Stage Chronic Kidney Disease Drugs market size will reach US$ million by 2031.
Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD - Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Late Stage Chronic Kidney Disease Drugs Industry Forecast” looks at past sales and reviews total world Late Stage Chronic Kidney Disease Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Late Stage Chronic Kidney Disease Drugs sales for 2025 through 2031. With Late Stage Chronic Kidney Disease Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Late Stage Chronic Kidney Disease Drugs industry.
This Insight Report provides a comprehensive analysis of the global Late Stage Chronic Kidney Disease Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Late Stage Chronic Kidney Disease Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Late Stage Chronic Kidney Disease Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Late Stage Chronic Kidney Disease Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Late Stage Chronic Kidney Disease Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Late Stage Chronic Kidney Disease Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD - Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Late Stage Chronic Kidney Disease Drugs Industry Forecast” looks at past sales and reviews total world Late Stage Chronic Kidney Disease Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Late Stage Chronic Kidney Disease Drugs sales for 2025 through 2031. With Late Stage Chronic Kidney Disease Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Late Stage Chronic Kidney Disease Drugs industry.
This Insight Report provides a comprehensive analysis of the global Late Stage Chronic Kidney Disease Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Late Stage Chronic Kidney Disease Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Late Stage Chronic Kidney Disease Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Late Stage Chronic Kidney Disease Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Late Stage Chronic Kidney Disease Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Late Stage Chronic Kidney Disease Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Calcimimetics
- Vitamin D Sterols
- Potassium Binders
- Others
- Hospital Pharmacies
- Online Pharnacies
- Retail Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AbbVie
- Amgen
- Ardelyx
- AstraZeneca
- Deltanoid
- Akebia Therapeutics
- Kyowa Hakko Kirin
- OPKO Health
- Vifor Pharma
- Sanofi
- Shield Therapeutics
- Shire
- Spectrum
- ZS Pharma
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Late Stage Chronic Kidney Disease Drugs Market Size (2020-2031)
2.1.2 Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Late Stage Chronic Kidney Disease Drugs by Country/Region (2020, 2024 & 2031)
2.2 Late Stage Chronic Kidney Disease Drugs Segment by Type
2.2.1 Calcimimetics
2.2.2 Vitamin D Sterols
2.2.3 Potassium Binders
2.2.4 Others
2.3 Late Stage Chronic Kidney Disease Drugs Market Size by Type
2.3.1 Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
2.4 Late Stage Chronic Kidney Disease Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Online Pharnacies
2.4.3 Retail Pharmacies
2.5 Late Stage Chronic Kidney Disease Drugs Market Size by Application
2.5.1 Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
3 LATE STAGE CHRONIC KIDNEY DISEASE DRUGS MARKET SIZE BY PLAYER
3.1 Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Player
3.1.1 Global Late Stage Chronic Kidney Disease Drugs Revenue by Player (2020-2025)
3.1.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Player (2020-2025)
3.2 Global Late Stage Chronic Kidney Disease Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LATE STAGE CHRONIC KIDNEY DISEASE DRUGS BY REGION
4.1 Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025)
4.2 Global Late Stage Chronic Kidney Disease Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
4.4 APAC Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
4.5 Europe Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
4.6 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025)
5.2 Americas Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
5.3 Americas Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025)
6.2 APAC Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
6.3 APAC Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025)
7.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs by Region (2020-2025)
8.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
8.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE DRUGS MARKET FORECAST
10.1 Global Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.1.1 Global Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.1.2 Americas Late Stage Chronic Kidney Disease Drugs Forecast
10.1.3 APAC Late Stage Chronic Kidney Disease Drugs Forecast
10.1.4 Europe Late Stage Chronic Kidney Disease Drugs Forecast
10.1.5 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Forecast
10.2 Americas Late Stage Chronic Kidney Disease Drugs Forecast by Country (2026-2031)
10.2.1 United States Market Late Stage Chronic Kidney Disease Drugs Forecast
10.2.2 Canada Market Late Stage Chronic Kidney Disease Drugs Forecast
10.2.3 Mexico Market Late Stage Chronic Kidney Disease Drugs Forecast
10.2.4 Brazil Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3 APAC Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.3.1 China Late Stage Chronic Kidney Disease Drugs Market Forecast
10.3.2 Japan Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.3 Korea Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.4 Southeast Asia Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.5 India Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.6 Australia Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4 Europe Late Stage Chronic Kidney Disease Drugs Forecast by Country (2026-2031)
10.4.1 Germany Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.2 France Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.3 UK Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.4 Italy Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.5 Russia Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.5.1 Egypt Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5.2 South Africa Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5.3 Israel Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5.4 Turkey Market Late Stage Chronic Kidney Disease Drugs Forecast
10.6 Global Late Stage Chronic Kidney Disease Drugs Forecast by Type (2026-2031)
10.7 Global Late Stage Chronic Kidney Disease Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Late Stage Chronic Kidney Disease Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Late Stage Chronic Kidney Disease Drugs Product Offered
11.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Late Stage Chronic Kidney Disease Drugs Product Offered
11.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 Ardelyx
11.3.1 Ardelyx Company Information
11.3.2 Ardelyx Late Stage Chronic Kidney Disease Drugs Product Offered
11.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Ardelyx Main Business Overview
11.3.5 Ardelyx Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Late Stage Chronic Kidney Disease Drugs Product Offered
11.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Deltanoid
11.5.1 Deltanoid Company Information
11.5.2 Deltanoid Late Stage Chronic Kidney Disease Drugs Product Offered
11.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Deltanoid Main Business Overview
11.5.5 Deltanoid Latest Developments
11.6 Akebia Therapeutics
11.6.1 Akebia Therapeutics Company Information
11.6.2 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
11.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Akebia Therapeutics Main Business Overview
11.6.5 Akebia Therapeutics Latest Developments
11.7 Kyowa Hakko Kirin
11.7.1 Kyowa Hakko Kirin Company Information
11.7.2 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product Offered
11.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Kyowa Hakko Kirin Main Business Overview
11.7.5 Kyowa Hakko Kirin Latest Developments
11.8 OPKO Health
11.8.1 OPKO Health Company Information
11.8.2 OPKO Health Late Stage Chronic Kidney Disease Drugs Product Offered
11.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 OPKO Health Main Business Overview
11.8.5 OPKO Health Latest Developments
11.9 Vifor Pharma
11.9.1 Vifor Pharma Company Information
11.9.2 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
11.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Vifor Pharma Main Business Overview
11.9.5 Vifor Pharma Latest Developments
11.10 Sanofi
11.10.1 Sanofi Company Information
11.10.2 Sanofi Late Stage Chronic Kidney Disease Drugs Product Offered
11.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Sanofi Main Business Overview
11.10.5 Sanofi Latest Developments
11.11 Shield Therapeutics
11.11.1 Shield Therapeutics Company Information
11.11.2 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
11.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Shield Therapeutics Main Business Overview
11.11.5 Shield Therapeutics Latest Developments
11.12 Shire
11.12.1 Shire Company Information
11.12.2 Shire Late Stage Chronic Kidney Disease Drugs Product Offered
11.12.3 Shire Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Shire Main Business Overview
11.12.5 Shire Latest Developments
11.13 Spectrum
11.13.1 Spectrum Company Information
11.13.2 Spectrum Late Stage Chronic Kidney Disease Drugs Product Offered
11.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Spectrum Main Business Overview
11.13.5 Spectrum Latest Developments
11.14 ZS Pharma
11.14.1 ZS Pharma Company Information
11.14.2 ZS Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
11.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 ZS Pharma Main Business Overview
11.14.5 ZS Pharma Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Late Stage Chronic Kidney Disease Drugs Market Size (2020-2031)
2.1.2 Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Late Stage Chronic Kidney Disease Drugs by Country/Region (2020, 2024 & 2031)
2.2 Late Stage Chronic Kidney Disease Drugs Segment by Type
2.2.1 Calcimimetics
2.2.2 Vitamin D Sterols
2.2.3 Potassium Binders
2.2.4 Others
2.3 Late Stage Chronic Kidney Disease Drugs Market Size by Type
2.3.1 Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
2.4 Late Stage Chronic Kidney Disease Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Online Pharnacies
2.4.3 Retail Pharmacies
2.5 Late Stage Chronic Kidney Disease Drugs Market Size by Application
2.5.1 Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
3 LATE STAGE CHRONIC KIDNEY DISEASE DRUGS MARKET SIZE BY PLAYER
3.1 Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Player
3.1.1 Global Late Stage Chronic Kidney Disease Drugs Revenue by Player (2020-2025)
3.1.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Player (2020-2025)
3.2 Global Late Stage Chronic Kidney Disease Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LATE STAGE CHRONIC KIDNEY DISEASE DRUGS BY REGION
4.1 Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025)
4.2 Global Late Stage Chronic Kidney Disease Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
4.4 APAC Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
4.5 Europe Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
4.6 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025)
5.2 Americas Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
5.3 Americas Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025)
6.2 APAC Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
6.3 APAC Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025)
7.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs by Region (2020-2025)
8.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025)
8.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE DRUGS MARKET FORECAST
10.1 Global Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.1.1 Global Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.1.2 Americas Late Stage Chronic Kidney Disease Drugs Forecast
10.1.3 APAC Late Stage Chronic Kidney Disease Drugs Forecast
10.1.4 Europe Late Stage Chronic Kidney Disease Drugs Forecast
10.1.5 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Forecast
10.2 Americas Late Stage Chronic Kidney Disease Drugs Forecast by Country (2026-2031)
10.2.1 United States Market Late Stage Chronic Kidney Disease Drugs Forecast
10.2.2 Canada Market Late Stage Chronic Kidney Disease Drugs Forecast
10.2.3 Mexico Market Late Stage Chronic Kidney Disease Drugs Forecast
10.2.4 Brazil Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3 APAC Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.3.1 China Late Stage Chronic Kidney Disease Drugs Market Forecast
10.3.2 Japan Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.3 Korea Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.4 Southeast Asia Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.5 India Market Late Stage Chronic Kidney Disease Drugs Forecast
10.3.6 Australia Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4 Europe Late Stage Chronic Kidney Disease Drugs Forecast by Country (2026-2031)
10.4.1 Germany Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.2 France Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.3 UK Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.4 Italy Market Late Stage Chronic Kidney Disease Drugs Forecast
10.4.5 Russia Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Forecast by Region (2026-2031)
10.5.1 Egypt Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5.2 South Africa Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5.3 Israel Market Late Stage Chronic Kidney Disease Drugs Forecast
10.5.4 Turkey Market Late Stage Chronic Kidney Disease Drugs Forecast
10.6 Global Late Stage Chronic Kidney Disease Drugs Forecast by Type (2026-2031)
10.7 Global Late Stage Chronic Kidney Disease Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Late Stage Chronic Kidney Disease Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Late Stage Chronic Kidney Disease Drugs Product Offered
11.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Late Stage Chronic Kidney Disease Drugs Product Offered
11.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 Ardelyx
11.3.1 Ardelyx Company Information
11.3.2 Ardelyx Late Stage Chronic Kidney Disease Drugs Product Offered
11.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Ardelyx Main Business Overview
11.3.5 Ardelyx Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Late Stage Chronic Kidney Disease Drugs Product Offered
11.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Deltanoid
11.5.1 Deltanoid Company Information
11.5.2 Deltanoid Late Stage Chronic Kidney Disease Drugs Product Offered
11.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Deltanoid Main Business Overview
11.5.5 Deltanoid Latest Developments
11.6 Akebia Therapeutics
11.6.1 Akebia Therapeutics Company Information
11.6.2 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
11.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Akebia Therapeutics Main Business Overview
11.6.5 Akebia Therapeutics Latest Developments
11.7 Kyowa Hakko Kirin
11.7.1 Kyowa Hakko Kirin Company Information
11.7.2 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product Offered
11.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Kyowa Hakko Kirin Main Business Overview
11.7.5 Kyowa Hakko Kirin Latest Developments
11.8 OPKO Health
11.8.1 OPKO Health Company Information
11.8.2 OPKO Health Late Stage Chronic Kidney Disease Drugs Product Offered
11.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 OPKO Health Main Business Overview
11.8.5 OPKO Health Latest Developments
11.9 Vifor Pharma
11.9.1 Vifor Pharma Company Information
11.9.2 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
11.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Vifor Pharma Main Business Overview
11.9.5 Vifor Pharma Latest Developments
11.10 Sanofi
11.10.1 Sanofi Company Information
11.10.2 Sanofi Late Stage Chronic Kidney Disease Drugs Product Offered
11.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Sanofi Main Business Overview
11.10.5 Sanofi Latest Developments
11.11 Shield Therapeutics
11.11.1 Shield Therapeutics Company Information
11.11.2 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
11.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Shield Therapeutics Main Business Overview
11.11.5 Shield Therapeutics Latest Developments
11.12 Shire
11.12.1 Shire Company Information
11.12.2 Shire Late Stage Chronic Kidney Disease Drugs Product Offered
11.12.3 Shire Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Shire Main Business Overview
11.12.5 Shire Latest Developments
11.13 Spectrum
11.13.1 Spectrum Company Information
11.13.2 Spectrum Late Stage Chronic Kidney Disease Drugs Product Offered
11.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Spectrum Main Business Overview
11.13.5 Spectrum Latest Developments
11.14 ZS Pharma
11.14.1 ZS Pharma Company Information
11.14.2 ZS Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
11.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 ZS Pharma Main Business Overview
11.14.5 ZS Pharma Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Late Stage Chronic Kidney Disease Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Calcimimetics
Table 4. Major Players of Vitamin D Sterols
Table 5. Major Players of Potassium Binders
Table 6. Major Players of Others
Table 7. Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Table 10. Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Table 13. Global Late Stage Chronic Kidney Disease Drugs Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Player (2020-2025)
Table 15. Late Stage Chronic Kidney Disease Drugs Key Players Head office and Products Offered
Table 16. Late Stage Chronic Kidney Disease Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Table 21. Global Late Stage Chronic Kidney Disease Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Country (2020-2025)
Table 25. Americas Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Table 27. Americas Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Table 29. APAC Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Table 31. APAC Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Country (2020-2025)
Table 35. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Late Stage Chronic Kidney Disease Drugs
Table 41. Key Market Challenges & Risks of Late Stage Chronic Kidney Disease Drugs
Table 42. Key Industry Trends of Late Stage Chronic Kidney Disease Drugs
Table 43. Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. AbbVie Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 48. AbbVie Late Stage Chronic Kidney Disease Drugs Product Offered
Table 49. AbbVie Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. AbbVie Main Business
Table 51. AbbVie Latest Developments
Table 52. Amgen Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 53. Amgen Late Stage Chronic Kidney Disease Drugs Product Offered
Table 54. Amgen Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Amgen Main Business
Table 56. Amgen Latest Developments
Table 57. Ardelyx Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 58. Ardelyx Late Stage Chronic Kidney Disease Drugs Product Offered
Table 59. Ardelyx Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Ardelyx Main Business
Table 61. Ardelyx Latest Developments
Table 62. AstraZeneca Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 63. AstraZeneca Late Stage Chronic Kidney Disease Drugs Product Offered
Table 64. AstraZeneca Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. AstraZeneca Main Business
Table 66. AstraZeneca Latest Developments
Table 67. Deltanoid Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 68. Deltanoid Late Stage Chronic Kidney Disease Drugs Product Offered
Table 69. Deltanoid Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Deltanoid Main Business
Table 71. Deltanoid Latest Developments
Table 72. Akebia Therapeutics Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 73. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
Table 74. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 75. Akebia Therapeutics Main Business
Table 76. Akebia Therapeutics Latest Developments
Table 77. Kyowa Hakko Kirin Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 78. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product Offered
Table 79. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 80. Kyowa Hakko Kirin Main Business
Table 81. Kyowa Hakko Kirin Latest Developments
Table 82. OPKO Health Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 83. OPKO Health Late Stage Chronic Kidney Disease Drugs Product Offered
Table 84. OPKO Health Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 85. OPKO Health Main Business
Table 86. OPKO Health Latest Developments
Table 87. Vifor Pharma Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 88. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
Table 89. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 90. Vifor Pharma Main Business
Table 91. Vifor Pharma Latest Developments
Table 92. Sanofi Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 93. Sanofi Late Stage Chronic Kidney Disease Drugs Product Offered
Table 94. Sanofi Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 95. Sanofi Main Business
Table 96. Sanofi Latest Developments
Table 97. Shield Therapeutics Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 98. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
Table 99. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 100. Shield Therapeutics Main Business
Table 101. Shield Therapeutics Latest Developments
Table 102. Shire Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 103. Shire Late Stage Chronic Kidney Disease Drugs Product Offered
Table 104. Shire Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 105. Shire Main Business
Table 106. Shire Latest Developments
Table 107. Spectrum Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 108. Spectrum Late Stage Chronic Kidney Disease Drugs Product Offered
Table 109. Spectrum Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 110. Spectrum Main Business
Table 111. Spectrum Latest Developments
Table 112. ZS Pharma Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 113. ZS Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
Table 114. ZS Pharma Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 115. ZS Pharma Main Business
Table 116. ZS Pharma Latest Developments
Table 1. Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Late Stage Chronic Kidney Disease Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Calcimimetics
Table 4. Major Players of Vitamin D Sterols
Table 5. Major Players of Potassium Binders
Table 6. Major Players of Others
Table 7. Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Table 10. Late Stage Chronic Kidney Disease Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Table 13. Global Late Stage Chronic Kidney Disease Drugs Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Player (2020-2025)
Table 15. Late Stage Chronic Kidney Disease Drugs Key Players Head office and Products Offered
Table 16. Late Stage Chronic Kidney Disease Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Table 21. Global Late Stage Chronic Kidney Disease Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Country (2020-2025)
Table 25. Americas Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Table 27. Americas Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Table 29. APAC Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Table 31. APAC Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Country (2020-2025)
Table 35. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Late Stage Chronic Kidney Disease Drugs
Table 41. Key Market Challenges & Risks of Late Stage Chronic Kidney Disease Drugs
Table 42. Key Industry Trends of Late Stage Chronic Kidney Disease Drugs
Table 43. Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Late Stage Chronic Kidney Disease Drugs Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. AbbVie Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 48. AbbVie Late Stage Chronic Kidney Disease Drugs Product Offered
Table 49. AbbVie Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. AbbVie Main Business
Table 51. AbbVie Latest Developments
Table 52. Amgen Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 53. Amgen Late Stage Chronic Kidney Disease Drugs Product Offered
Table 54. Amgen Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Amgen Main Business
Table 56. Amgen Latest Developments
Table 57. Ardelyx Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 58. Ardelyx Late Stage Chronic Kidney Disease Drugs Product Offered
Table 59. Ardelyx Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Ardelyx Main Business
Table 61. Ardelyx Latest Developments
Table 62. AstraZeneca Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 63. AstraZeneca Late Stage Chronic Kidney Disease Drugs Product Offered
Table 64. AstraZeneca Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. AstraZeneca Main Business
Table 66. AstraZeneca Latest Developments
Table 67. Deltanoid Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 68. Deltanoid Late Stage Chronic Kidney Disease Drugs Product Offered
Table 69. Deltanoid Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Deltanoid Main Business
Table 71. Deltanoid Latest Developments
Table 72. Akebia Therapeutics Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 73. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
Table 74. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 75. Akebia Therapeutics Main Business
Table 76. Akebia Therapeutics Latest Developments
Table 77. Kyowa Hakko Kirin Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 78. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product Offered
Table 79. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 80. Kyowa Hakko Kirin Main Business
Table 81. Kyowa Hakko Kirin Latest Developments
Table 82. OPKO Health Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 83. OPKO Health Late Stage Chronic Kidney Disease Drugs Product Offered
Table 84. OPKO Health Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 85. OPKO Health Main Business
Table 86. OPKO Health Latest Developments
Table 87. Vifor Pharma Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 88. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
Table 89. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 90. Vifor Pharma Main Business
Table 91. Vifor Pharma Latest Developments
Table 92. Sanofi Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 93. Sanofi Late Stage Chronic Kidney Disease Drugs Product Offered
Table 94. Sanofi Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 95. Sanofi Main Business
Table 96. Sanofi Latest Developments
Table 97. Shield Therapeutics Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 98. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product Offered
Table 99. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 100. Shield Therapeutics Main Business
Table 101. Shield Therapeutics Latest Developments
Table 102. Shire Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 103. Shire Late Stage Chronic Kidney Disease Drugs Product Offered
Table 104. Shire Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 105. Shire Main Business
Table 106. Shire Latest Developments
Table 107. Spectrum Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 108. Spectrum Late Stage Chronic Kidney Disease Drugs Product Offered
Table 109. Spectrum Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 110. Spectrum Main Business
Table 111. Spectrum Latest Developments
Table 112. ZS Pharma Details, Company Type, Late Stage Chronic Kidney Disease Drugs Area Served and Its Competitors
Table 113. ZS Pharma Late Stage Chronic Kidney Disease Drugs Product Offered
Table 114. ZS Pharma Late Stage Chronic Kidney Disease Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 115. ZS Pharma Main Business
Table 116. ZS Pharma Latest Developments
LIST OF FIGURES
Figure 1. Late Stage Chronic Kidney Disease Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Late Stage Chronic Kidney Disease Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Late Stage Chronic Kidney Disease Drugs Sales Market Share by Country/Region (2024)
Figure 8. Late Stage Chronic Kidney Disease Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type in 2024
Figure 10. Late Stage Chronic Kidney Disease Drugs in Hospital Pharmacies
Figure 11. Global Late Stage Chronic Kidney Disease Drugs Market: Hospital Pharmacies (2020-2025) & ($ millions)
Figure 12. Late Stage Chronic Kidney Disease Drugs in Online Pharnacies
Figure 13. Global Late Stage Chronic Kidney Disease Drugs Market: Online Pharnacies (2020-2025) & ($ millions)
Figure 14. Late Stage Chronic Kidney Disease Drugs in Retail Pharmacies
Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market: Retail Pharmacies (2020-2025) & ($ millions)
Figure 16. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application in 2024
Figure 17. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Player in 2024
Figure 18. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Figure 19. Americas Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 20. APAC Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 21. Europe Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 23. Americas Late Stage Chronic Kidney Disease Drugs Value Market Share by Country in 2024
Figure 24. United States Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region in 2024
Figure 29. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Figure 30. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Figure 31. China Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 35. India Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Country in 2024
Figure 38. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Figure 39. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Figure 40. Germany Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 41. France Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 54. APAC Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 55. Europe Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 57. United States Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 58. Canada Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 59. Mexico Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 60. Brazil Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 61. China Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 62. Japan Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 63. Korea Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 65. India Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 66. Australia Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 67. Germany Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 68. France Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 69. UK Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 70. Italy Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 71. Russia Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 72. Egypt Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 73. South Africa Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 74. Israel Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 75. Turkey Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 76. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 1. Late Stage Chronic Kidney Disease Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Late Stage Chronic Kidney Disease Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Late Stage Chronic Kidney Disease Drugs Sales Market Share by Country/Region (2024)
Figure 8. Late Stage Chronic Kidney Disease Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type in 2024
Figure 10. Late Stage Chronic Kidney Disease Drugs in Hospital Pharmacies
Figure 11. Global Late Stage Chronic Kidney Disease Drugs Market: Hospital Pharmacies (2020-2025) & ($ millions)
Figure 12. Late Stage Chronic Kidney Disease Drugs in Online Pharnacies
Figure 13. Global Late Stage Chronic Kidney Disease Drugs Market: Online Pharnacies (2020-2025) & ($ millions)
Figure 14. Late Stage Chronic Kidney Disease Drugs in Retail Pharmacies
Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market: Retail Pharmacies (2020-2025) & ($ millions)
Figure 16. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application in 2024
Figure 17. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Player in 2024
Figure 18. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Figure 19. Americas Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 20. APAC Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 21. Europe Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size 2020-2025 ($ millions)
Figure 23. Americas Late Stage Chronic Kidney Disease Drugs Value Market Share by Country in 2024
Figure 24. United States Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region in 2024
Figure 29. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Figure 30. APAC Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Figure 31. China Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 35. India Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Country in 2024
Figure 38. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Figure 39. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Figure 40. Germany Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 41. France Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Late Stage Chronic Kidney Disease Drugs Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 54. APAC Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 55. Europe Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 57. United States Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 58. Canada Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 59. Mexico Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 60. Brazil Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 61. China Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 62. Japan Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 63. Korea Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 65. India Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 66. Australia Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 67. Germany Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 68. France Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 69. UK Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 70. Italy Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 71. Russia Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 72. Egypt Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 73. South Africa Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 74. Israel Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 75. Turkey Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
Figure 76. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Late Stage Chronic Kidney Disease Drugs Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Late Stage Chronic Kidney Disease Drugs Market Size 2026-2031 ($ millions)
More Publications
Global Leber Congenital Amaurosis (LCA) Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
73 pages
